Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexi...(iological samples in its proprietary tes...)

Date:10/15/2008

iological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance, and future market opportunities and market size. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and practices; customer and market acceptance of the product; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any su
'/>"/>

SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
2. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
3. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
4. Cepheid to Webcast Upcoming Financial Presentations
5. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
6. Cepheid Reports Second Quarter Revenue of $42.1 Million
7. Cepheid to Webcast Analyst Event
8. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
9. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
10. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
11. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization